Assessment of hearing dysfunction in patients with Graves’ disease and thyroid eye disease without or with teprotumumab

Published: 27 August 2024| Version 1 | DOI: 10.17632/tgj5v33xkk.1
Contributor:
Terry Smith

Description

Supplemental Data.

Files

Categories

Adverse Event, Hearing Loss

Licence